Farzan Clinical Research and Novo Nordisk signed a contract. According to this contract, Farzan Clinical Research provides medical and scientific writing services to Novonordisk. The major topic is about Diabetes Type II.

Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 34,700 employees in 75 countries, and markets its products in 180 countries.

Farzan Clinical Research is the first Iranian Clinical Research Organization (CRO). Farzan Clinical Research is now an important partner for many Universities, research centers, scientific societies as well as pharmaceutical and medical device industry. After 10 years experience in providing medical research services as Farzan Institute for Science, Research & Technology, Farzan Clinical Research was founded in Feb 2008 as the first Iranian registered CRO and now offers Clinical Trial Management, Clinical Trial Monitoring, Data Management, Biostatistics and Medical Writing services. Farzan Clinical Research is certified by Ministry of Health and Medical Education- Food and Drug Organization (FDA) – Islamic Republic of Iran. The Best National Entrepreneur prize was awarded to Farzan Clinical Research and Farzan was acknowledged by President of Islamic Republic of Iran in July 2011.